Last updated: January 29, 2024
Sponsor: Aga Khan University
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetes And Hypertension
Diabetes Prevention
Treatment
Behavioural modification counselling
Fermented cereal based product
Fermented milk product
Clinical Study ID
NCT05960019
2022-104
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Clinically diagnosed pre-diabetes (diagnosed less than 6 months ago), defined as HbA1cbetween 5.7% and 6.4%,
- Both male and female prediabetic individuals
- Aged between 18 and 65 years
- Seeking clinic services at the selected AKU-outreach facilities for at least 3 visits (including seeking services for separate reasons other than pre-diabetes for thepurpose of determining affiliation)
Exclusion
Exclusion Criteria:
- Currently on any of the following:
- glucose lowering medication (including insulin therapy)
- steroid therapy,
- immunosuppressive therapy,
- medication for gastric disease,
- warfarin or other coumarin derivates,
- Vitamin C or E, Iron or B12
- erythropoietin
- antiretrovirals
- ribavirin
- dapsone
- Chronic use (defined as consumption of more than 3 months) of non-steroidalanti-inflammatory drugs or aspirin
- Individuals that have consumed antibiotics in the last month.
- Individuals that regularly consume fermented foods or took nutritional supplementsincluding probiotics during the 3 months prior to screening. Regular consumption shallbe defined as consuming at least 250ml of fermented foods on six days in a week.
- Individuals who at the time of enrolment are smokers, regularly consume alcohol (defined as having had at least 12 drinks in the past year but 3 drinks or fewer perweek, on average over the past year) or are suffering from drug addiction includingchronic opiate use.
- Individuals with a history of gastrointestinal surgery (gastrectomy, bariatricsurgery, or colostomy), splenectomy or gastrointestinal malignancy.
- Individuals known to be:
- HIV+ve,
- suffering from blood disorders such as Reticulocytosis or any form of Anaemia (including Iron deficiency, B12 Deficiency) or Haemoglobinopathies.
- Pregnant or lactating,
- with serious organic or metabolic conditions [such as malignant disease,pancreatitis, endocarditis, liver, or severe kidney disease (serum creatininelevel above the normal range or macroalbuminuria including chronic renalfailure), severe pulmonary or heart disease], splenomegaly, rheumatoid arthritis,hypertriglyceridemia, in a terminal stage of illness, or experiencing acute orsevere episodes of mental illness at the time of enrolment.
- Individuals with allergies to dairy or cereal products such as millet.
Study Design
Total Participants: 252
Treatment Group(s): 3
Primary Treatment: Behavioural modification counselling
Phase:
Study Start date:
January 17, 2024
Estimated Completion Date:
December 17, 2024
Connect with a study center
Aga Khan Outreach Facilities
Kiambu,
KenyaActive - Recruiting
Aga Khan Outreach Facilities
Nairobi,
KenyaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.